Revisiting Weight-Normalized SUV and Lean-Body-Mass–Normalized SUV in PET Studies

Ismet Sarikaya[1], Ahmed N. Albatineh[2], and Ali Sarikaya[3]

[1]Department of Nuclear Medicine, Faculty of Medicine, Kuwait University, and Mubarak Al-Kabeer Hospital, Jabriya, Kuwait;
[2]Department of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Safat, Kuwait; and
[3]Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey

SUV normalized by total body weight is affected by the amount of body fat. The SUV of normal tissues and lesions is higher (overestimated) in obese patients than in patients with a normal body mass index (BMI). SUL (SUV normalized by lean body mass [LBM]) is recommended for more accurate SUV results. Given the importance of a quantitative PET parameter, particularly when comparing PET studies, we aimed to revisit the effect of obesity on SUV, measuring SUL in normal-BMI patients and obese patients and testing the effect of the amount of LBM. **Methods:** ^{18}F-FDG whole-body images of adult patients were analyzed retrospectively. We measured both SUV_{max} and SUV_{mean} in the blood pool and liver of patients with a normal BMI (18.5–24.9) and a high BMI (≥30) (obese). In all patients, we calculated LBM via an equation using patient height and weight and corrected all SUVs to SULs. Mean (±SD) SUVs and SULs were compared under various circumstances. Scatterplots were generated for weight and SUV–SUL differences. **Results:** SUV_{mean} in the liver and blood pool was significantly higher in obese patients (30 patients) than in patients with a normal BMI (20 patients) (4.1 ± 0.7 and 3.0 ± 0.5, respectively, in liver, vs. 3.2 ± 0.6 and 2.4 ± 0.4, respectively, in blood pool; $P < 0.001$). SUL_{mean} was significantly lower in both liver and blood pool in all patients, being approximately 75% of SUV_{mean} in patients with a normal BMI and 55% of SUV_{mean} in obese patients ($P < 0.001$). SUL_{mean} in the liver and blood pool did not significantly differ between obese patients and normal-BMI patients ($P > 0.05$). The SUV–SUL difference was significantly higher in obese patients than in patients with a normal BMI ($P < 0.001$). These statistical results were the same when SUV_{max} and SUL_{max} were compared. **Conclusion:** SUV overestimates metabolic activity in all patients, and this overestimation is more significant in obese patients than in patients with a normal BMI. SUL is not affected by body weight or the amount of LBM.

Key Words: SUV; SUL; lean body mass; weight; PET

SUV is a commonly used PET parameter to measure the uptake of various radiopharmaceuticals, mainly ^{18}F-FDG, in normal tissues and lesions (1–3). SUV is simply the ratio of activity concentration in the target tissue or lesion to activity concentration in the whole body:

$$SUV = kBq/cm^3 \text{ (lesion or target tissue)}/ \\ [\text{injected activity (MBq)/patient weight (kg)}].$$

This equation assumes that injected activity is uniformly distributed in the whole body and that 1 cm^3 of tissue weighs 1 g (4). Activity in the lesion or target tissue is decay-corrected.

In routine, many hospitals still use the patient's weight to normalize SUV, although it is known that SUV is overestimated in obese patients (5–7). This consideration is particularly important when one is comparing the new and old PET studies of a patient whose weight has significantly changed or of a child who has significantly grown between studies. Obese patients have a high amount of body fat. ^{18}F-FDG accumulation in white fat is very low in the fasting state, and PET studies are obtained in the fasting state (8). On the other hand, a significant accumulation of ^{18}F-FDG is seen in brown fat, mostly in children and underweight adults, particularly women, and in cold temperatures (9,10). White fat contributes a significant amount to total body weight. Among young women (20–39 y old), fat makes up 20%–25% of the total body weight in those with a normal body mass index (BMI) (18.5–24.9), 32%–35% in those with a BMI of 25–29.9 (overweight), and 38%–40% in those with a BMI of 30 or higher (obese) (11). These values are lower in men (11). The mean concentration of activity in the patient's body (MBq/kg or MBq/L) decreases with increasing body weight, causing erroneously higher SUVs in obese patients.

As an alternative to SUV (normalized by total body weight), SUL has been recommended (SUV normalized by lean body mass [LBM]), because ^{18}F-FDG accumulation in fat is minimal and the percentage of fat is high in obese people (5). There are various ways of measuring LBM. It is generally calculated through predictive equations using height and body weight (12). Semidirect measurements of

LBM such as bioelectric impedance analysis, dual-energy x-ray absorptiometry, CT, and MRI can provide more accurate results (13). Using the most accurate method to measure LBM will provide a more accurate SUL. A standard formula for calculating LBM will allow more accurate comparison of PET studies.

Although SUL is highly recommended instead of SUV to calculate the metabolic activity of lesions and tissues, particularly in obese patients, SUV is still commonly used. Given the importance of a quantitative PET parameter, particularly when comparing PET studies, we aimed to revisit the effect of body fat on SUV, to measure SUL not only in obese patients but also in patients with a normal BMI, and to test the effect of the amount of LBM on SUL.

MATERIALS AND METHODS

In this retrospective study, whole-body ^{18}F-FDG/CT images of adult patients were selected for further analysis. The study was approved by the ethics committee of the Kuwait Ministry of Health, and the requirement for informed consent was waived.

The ^{18}F-FDG PET/CT images were obtained at Mubarak Al-Kabeer Hospital, mainly for oncology patients, on a Gemini time-of-flight PET/CT camera (Philips). The images were acquired 60 min after intravenous injection of 222 MBq (6 mCi) of ^{18}F-FDG for a 70-kg patient (3.17 MBq/kg). Blood glucose levels were measured using a glucometer before the ^{18}F-FDG was injected; at our institute we usually do not injected ^{18}F-FDG unless the blood glucose is no higher than 150 mg/dL. A low-dose CT scan was first obtained for attenuation correction and anatomic localization. Afterward, the PET acquisition took place at a speed of 2–3 min per bed position from the top of the head to the mid thighs or toes. PET images were corrected for attenuation on the basis of the CT data, were reconstructed using a standard iterative algorithm, and were reformatted into transaxial, coronal, and sagittal views. Maximum-intensity projections were also generated. Both attenuation-corrected and uncorrected PET images were reviewed, as well as PET/CT fusion images.

We recorded each patient's weight, height, and net injected activity (^{18}F-FDG dose before injection minus residual activity in the syringe after injection).

We measured SUV_{max} and SUV_{mean} in the normal liver and blood pool in patients with a normal BMI (18.5–24.9) and a high BMI ($\geq$30). SUV_{mean} more accurately estimates activity in the blood pool and liver; however, because SUV_{max} is used to assess the lesions, we also measured SUV_{max} in the blood pool and liver to see if any results differed when SUV_{max} and SUV_{mean} were corrected to SUL_{max} and SUL_{mean}. A 1 cm^2 spheric region of interest was placed over the right hepatic lobe in a normal-appearing area, and a 1 cm^2 spheric region of interest was placed over the blood pool in the left or right atrium, excluding the atrial wall. If there was activity in the atrial wall, we used the ventricular cavity.

We determined LBM via an online calculator by entering the patient height and weight, and we then calculated the SUL for each SUV (12).

Data management and statistical analysis were performed using SPSS software (version 25.0; IBM Corp.). Mean ($\pm$SD) was calculated for the blood-pool and liver SUV_{max}, SUV_{mean}, SUL_{max}, and SUL_{mean}; the injected doses; and the LBMs. To compare the values in 2 patient groups (patients with a normal BMI and obese patients), 2-sample t testing was used if the data showed normality according to the Shapiro–Wilk test; otherwise, the nonparametric Mann–Whitney U test was used. To compare the values in the same patient group, a paired t test was conducted if the mean of differences were normally distributed; otherwise, the Wilcoxon signed-rank test on the differences was used. All tests were 2-tailed, and a P value of less than 0.05 was considered statistically significant. Scatterplots were also generated for weight and SUV–SUL differences. We used Spearman rank correlation to quantify the strength of relationships between weight and SUV–SUL differences.

RESULTS

We evaluated the ^{18}F-FDG PET/CT whole-body images of 50 patients: 20 with a normal BMI (mean age, 61.3 y; range, 43–74 y; 6 women and 14 men) and 30 with a high BMI (obese) (mean age, 61.7 y; range, 30–77 y; 19 women and 11 men). The injected ^{18}F-FDG activity was 223.4 $\pm$ 28.1 MBq ($\sim$6 mCi) in patients with a normal BMI and 299.9 $\pm$ 23.3 MBq ($\sim$8 mCi) in obese patients. The SUV_{max}, SUV_{mean}, SUL_{max}, and SUL_{mean} of the blood pool and liver are shown in Figures 1 and 2.

SUV_{mean} and SUV_{max} in the liver and blood pool were significantly higher in obese patients than in normal-BMI patients ($P < 0.001$); SUV_{mean} was 33%–36% higher, and SUV_{max} was 36%–41% higher.

SUL_{mean} and SUL_{max} in liver and blood pool were significantly lower than SUV_{mean} and SUV_{max} in all patients. SULs were approximately 75% of SUVs in patients with a normal


FIGURE 1. Mean $\pm$ SD SUV_{mean} and SUL_{mean} of liver and blood pool in patients with normal BMI and obese patients. BP = blood pool; NL = normal BMI.

FIGURE 2. Mean ± SD SUV_{max} and SUL_{max} of liver and blood pool in patients with normal BMI and obese patients. BP = blood pool; NL = normal BMI.

DISCUSSION

Visual assessment of PET images for areas of abnormal uptake is adequate and accurate. However, a quantitative or semiquantitative method can better assess such parameters as metabolic activity, perfusion, or the receptor density of lesions and tissues, depending on the PET study. Such assessments are important to estimate the grade of malignancy, to calculate the dose of therapeutic agents, and to compare posttreatment studies with pretreatment studies (14–16).

SUV is the most commonly used PET parameter to assess uptake of various radiopharmaceuticals in lesions and normal tissues. SUV generally accurately estimates the degree of uptake in lesions and normal tissues but is affected by various patient, biologic, and technical factors that can cause over- or underestimation of activity. ^{18}F-FDG uptake can be affected by many factors, such as suboptimal patient preparation; high blood glucose and insulin levels; the presence of diabetes; the patient's BMI, age, and sex; the imaging start time after radiotracer injection; significant extravasation of activity; the image acquisition and reconstruction parameters; conditions during the postinjection uptake period; inaccurate entry of patient weight, height, and injected activity into the computer; the effect of CT contrast material on attenuation-corrected PET images; patient and organ motion; the presence of other diseases; and the effects of medications (17–22).

In overweight people, SUV is usually overestimated in lesions and normal tissues (5,6). SUL more accurately estimates radiopharmaceutical uptake and compares PET studies. Zasadny et al. reported that in heavy patients, the SUVs of blood, liver, and spleen were up to twice those in lighter patients (5). SUL provided lower values than SUV in

BMI and 55% of SUVs in obese patients ($P < 0.001$). These comparisons show that SUVs were overestimated in all patients (both normal-BMI and high-BMI patients), but more so in obese patients.

SUL_{mean} and SUL_{max} in liver and blood pool did not significantly differ between obese patients and normal-BMI patients ($P > 0.05$).

When comparing obese patients with different amount of LBM (50.3 ± 1.7 kg vs. 59.1 ± 2.8 kg, 10 patients in each subgroup), we found that SULs did not significantly differ ($P > 0.05$) (Table 1).

The differences between liver and blood-pool SUV and SUL (SUV minus SUL) were significantly higher in obese patients than in normal-BMI patients ($P < 0.001$) (Fig. 3). Scatterplots of the relationship between weight and SUV–SUL differences are seen in Figure 4; there is clearly a positive linear relationship. The correlations between SUV–SUL differences and weight for liver SUV_{mean}, liver SUV_{max}, blood-pool SUV_{mean}, and blood-pool SUV_{max} were 0.727, 0.766, 0.673, and 0.729, respectively, and all were significant ($P < 0.001$).

TABLE 1
SUL_{max} and SUL_{mean} in Obese Patients with Different Amounts of LBM

Area	LBM ~ 50 kg (n = 10)	LBM ~ 60 kg (n = 10)	P*
Liver SUL_{max}	2.84 ± 0.406	2.92 ± 0.464	0.686
Liver SUL_{mean}	2.32 ± 0.278	2.26 ± 0.360	0.681
Blood-pool SUL_{max}	2.03 ± 0.275	2.14 ± 0.381	0.468
Blood-pool SUL_{mean}	1.72 ± 0.249	1.80 ± 0.306	0.529

*Based on 2-sample t test, because groups showed normality on Shapiro–Wilk test.
Data are mean ± SD.

FIGURE 3. Mean ± SD SUV–SUL differences (mean and maximum) in liver and blood pool in patients with normal BMI and obese patients.

FIGURE 4. Scatterplots of weight and SUV–SUL differences.

their study. In our obese patients, the SUVs of blood pool and liver were also significantly higher than expected normal values. SUV_{mean} was 33%–36% higher and SUV_{max} 36%–41% higher in obese patients than in patients with a normal BMI. As expected, SULs were lower than SUVs in all patients, even more so in obese patients. SULs were approximately 50% of SUVs in obese patients and 75% of SUVs in patients with a normal BMI.

The SULs of liver and blood pool did not significantly differ between obese patients and patients with a normal body BMI or between obese patients with higher and lower amounts of LBM. This finding shows that SUL is not affected by weight or amount of LBM. LBM can change over time within the same patient if there is a change in tissue composition, such as a gain in muscle. Figure 5 illustrates this principle.

Simply calculating the patient's LBM and using it to normalize the SUV will provide more accurate results than normalizing SUV by total body weight. For accurate comparison of PET studies, LBM should be calculated using a standardized method. However, in patients with a high amount of brown fat, SUL may be underestimated because brown fat takes up a significant amount of activity, causing competitive reduction of uptake in target tissues. On the other hand, if the brown fat is in an underweight patient, there may not be a significant difference between SUV and SUL because total weight will not significantly differ from

LBM. Studies assessing SUV in children found that their liver and tumor SUVs were lower than those in adults *(23,24)* and that SULs were also lower than normal adult values *(24)*.


FIGURE 5. Principle of patient who, at different times, had same body weight but different LBMs and was injected with same ^{18}F-FDG activity per body weight. In A, patient has more fat; in B, patient has more muscle. LBM activity (injected dose/LBM) is higher in A than in B, but target-area activity (kBq/mL) is also higher in A (because of smaller LBM volume in A and more available activity for target area). LBM activity is lower in B than in A, but target-area activity is also lower in B (because of higher volume of LBM and competitive reduction in target-area uptake caused by uptake in muscle). Both sides of SUL equation are higher in A and lower in B; as a result, SULs of target in A and B do not significantly differ. I/D = injected dose.

These studies recommended using body surface area–based calculation of SUV in pediatric patients (*23,24*). The lower SUVs and SULs in children could be due to their higher amount of brown fat, which could competitively reduce uptake in lesions and in other normal tissues.

Using SUL in all patients—whether they have a normal BMI or a high BMI—can provide more accurate results for comparison of PET studies in adults. However, currently, SUL can be used only in overweight and obese patients, not in patients with a normal BMI, because the current standard values (an SUV threshold of 2.5 for differentiating benign from malignant lesions, and reference SUVs for liver, blood pool, and other tissues) have been calculated from patients with a normal BMI or from mixtures of patients with various BMIs. If SUL is going to be used in routine practice, the standard values should be determined in large numbers of people with standard BMI.

The main limitation of this study may be its relatively small number of patients, but the number was enough to achieve an approximate assessment of various effects on SUVs and SULs. Another limitation is that we measured LBM using a predictive equation, but again, this method was acceptable for an approximate assessment of LBM. However, measurement by a more accurate method will provide more accurate results than measurement by a formula using weight and height (e.g., two patients of the same weight and height may have different amounts of fat and muscle and thus different LBMs).

CONCLUSION

SUV overestimates metabolic activity in all patients, and this overestimation is more significant in obese patients than in patients with a normal BMI. SUL is not affected by body weight or by the amount of LBM.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Leskinen-Kallio S, Någren K, Lehikoinen P, et al. Uptake of ^{11}C-methionine in breast cancer studied by PET: an association with the size of S-phase fraction. *Br J Cancer*. 1991;64:1121–1124.
2. Adler LP, Blair HF, Williams RP, et al. Grading liposarcomas with PET using [^{18}F]FDG. *J Comput Assist Tomogr*. 1990;14:960–962.
3. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. *Nucl Med Commun*. 2004;25:651–656.
4. Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. *Semin Ultrasound CT MR*. 2010;31:496–505.
5. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine 18]fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. *Radiology*. 1993;189:847–850.
6. Sugawara Y, Zasadny KR, Neuhoff AW, et al. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. *Radiology*. 1999;213:521–525.
7. Kim CK, Gupta NC, Chandramouli B, et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. *J Nucl Med*. 1994;35:164–167.
8. Tahari AK, Chien D, Azadi JR, et al. Optimum lean body formulation for correction of standardized uptake value in PET imaging. *J Nucl Med*. 2014;55:1481–1484.
9. Paul R, Kiuru A, Söderström KO, et al. Organ and tumor distribution of (^{18}F)-2-fluoro-2-deoxy-D-glucose in fasting and non-fasting rats. *Life Sci*. 1987;40:1609–1616.
10. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. *Eur J Nucl Med Mol Imaging*. 2002;29:1393–1398.
11. Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. *Am J Clin Nutr*. 2000;72:694–701.
12. Hume R. Prediction of lean body mass from height and weight. *J Clin Pathol*. 1966;19:389–391.
13. Devriese J, Beels L, Maes A, et al. Review of clinically accessible methods to determine lean body mass for normalization of standardized uptake values. *Q J Nucl Med Mol Imaging*. 2016;60:1–11.
14. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009;50(suppl 1):122S–150S.
15. Rodriguez M, Rehn S, Ahlström H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. *J Nucl Med*. 1995;36:1790–1796.
16. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. *J Nucl Med*. 2017;58(suppl 2):61S–66S.
17. Boellaard R. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med*. 2009;50(suppl 1):11S–20S.
18. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. *J Nucl Med*. 1993;34:1–6.
19. Sarikaya I, Sarikaya A, Sharma P. Assessing effect of various blood glucose levels on ^{18}F-FDG activity in the brain, liver and blood pool. *J Nucl Med Technol*. June 10, 2019 [Epub ahead of print].
20. Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. *J Nucl Med*. 2004;45:1519–1527.
21. Jaskowiak CJ, Bianco JA, Perlman SB, et al. Influence of reconstruction iterations on ^{18}F-FDG PET/CT standardized uptake values. *J Nucl Med*. 2005;46:424–428.
22. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. *J Nucl Med*. 2007;48:932–945.
23. Sugawara Y, Shulkin BL, Zasadny KR, et al. Standardized uptake values in pediatric patients: variations with patient characteristics and methods for correction [abstract]. *J Nucl Med*. 2000;41(suppl):196P.
24. Yeung HW, Sanches A, Squire OD, et al. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. *Eur J Nucl Med Mol Imaging*. 2002;29:61–66.